U.S. Immunologist James Patrick Allison: The Potential Cure for Cancer – The Number of People Killed by Cancer Annually World Wide, the Person Who Won the 2018 Nobel Prize Within Medicine, the Reason Allison Began Conducting Cancer Research, the Past Times of Allison During Childhood, Allison’s View of Scientific Toys Prompting Children to Become Scientists, the Age Allison Graduated Secondary School, the Laboratory Task U.S. Biochemist Barrie Kitto Assigned Allison During His Doctoral Program, Allison’s Idea to Increase the Efficiency of This Task, the Ability to Smoke Within the Laboratory During the 1960’s, the Explosion Allison Caused Within the Laboratory in 1966, the Reason Kitto Did Not Terminate Allison for This Outcome, the Most Important Lesson Allison Learned at the University of Texas, the Connection Between the Lymphatic System and the Circulatory System, the Concept of the “T Cell”, Allison Becoming Aware of the Properties of Asparaginase (Enzyme Which Breaks Down Asparagine) for Leukemia Within Children, Allison Utilizing Laboratory Rats to Study Asparaginase for Cancer Prevention and Reduction, How T Cells Determine Between Threatening and Non-Threatening Cells Within the Human Body, the Ambiguity of T Cells During the 1970’s and 1980’s, the Reason Allison Began Researching Cancer Without Scientific Literature, the Person Who Discovered the Molecule of the T Cell Which Recognizes Targets, the First Person to Successfully Isolate and Purify This Molecule, the Person Who Abolished Education Related to Evolution Within Texas in 1981, Allison Addressing the U.S. Senate Upon This Issue Within Texas, United States of America, the Result of This Speech, Allison Offered a Full Professorship, the Scientific View of Immunology During the 1980’s, the Person Who Discovered Cytotoxic T-Lymphocyte-Associated Protein (CTLA-4), the View of Cytotoxic T-Lymphocyte-Associated Protein During the Late 20th Century, How Allison Studied Cytotoxic T-Lymphocyte-Associated Protein Within Laboratory Rats, the Difficulty of Producing the Antibody Required to Study Cytotoxic T-Lymphocyte-Associated Protein, the Person Who Discovered That Cytotoxic T-Lymphocyte-Associated Protein is an Activating Receptor, Allison Believing U.S. Immunologist Peter Linsey to be Incorrect, U.S. Immunologist Max Krummell Creating the Cytotoxic T-Lymphocyte-Associated Protein Antibody Required by Allison, the Result of Allison’s Experiment With Cytotoxic T-Lymphocyte-Associated Protein, the View of Allison’s Discoveries by Scientists During the 1990’s, the Paradox of the Immune System and Cancerous Mutations, Allison Hypothesizing That Cancer Evolved to Evade Detection by the Immune System, Allison’s Idea to Block the Ability of Tumors to Evade Detection by the Immune System, U.S. Immunologist Daniel Leech Joining Allison’s Research, the Result of Allison’s Hypothesis Upon Tumors Within Laboratory Rats, the Time Required for the Human Body to Evolve to its Modern Day State, the Length of Time Allison Worked to Attempt to Create Medications Based Upon His Teams Discoveries, the Reason Allison’s Discoveries Did Not Yield Any Novel Medications, the Reason Pharmaceutical Companies Focused Upon Cardiac Medication Research Instead of Cancer Medication Research During the 2000’s, Cardiac Medication Profitability vs Cancer Medication Profitability, the Result of Allison Meeting With Multiple Pharmaceutical Organizations to Further Cancer Research, the Reason Pharmaceutical Organization Attorneys Recommended Not Investing Within Allison’s Research, the Reason U.S. Paralegal Malinda Bell (Allison’s Wife) Planned Vacations Without Telephone Service, Allison Attempting to Work With Smaller Biotechnology Organizations to Perform Cancer Research, the Cytotoxic T-Lymphocyte-Associated Protein Problem Allison Tasked U.S. Researcher Alan Korman With, the Person Korman Collaborated With for This Task, the Development of the Ipilimumab (Yervoy) Medication, How Phase I of a Medical Research Trial Works, How Phase I of a Medical Research Trial Dosaging Works, the Reason for This System, the Number of Medications Which Surpass Phase I of a Medical Research Trial, How Phase II of a Medical Research Trial Works, the Number of Medications Which Surpass Phase II of a Medical Research Trial, How Phase III of a Medical Research Trial Works, the Number Medications Which Surpass Phase III of a Medical Research Trial, How Phase IV of a Medical Research Trial Works, the Number of Medications Which Surpass Phase IV of a Medical Research Trial, the Various Efficacy Rate Thresholds of Medications, How Human Dosages of Ipilimumab Were Researched Within the Laboratory, the Number of Medications Which Meet the Standards Required to Continue Economic Funding Research, the Result of the Ipilimumab Medical Research Trials, How Ipilimumab is Administered to Patients, the Reason U.S. Physician Rachel Humphrey Left German Pharmaceutical Corporation Bayer, Humphrey Advocating Toward U.S. Pharmaceutical Corporation Bristol-Myers Squibb for the Continued Study of Ipilimumab, the Reason the U.S. Public Distrusted Bristol-Myers Squibb During the 2000’s, the Reason Bristol-Myers Squibb Did Not Want to Economically Fund Research of Ipilimumab, the Argument Humphrey Made to Convince Bristol-Myers Squibb to Economically Fund Research of Ipilimumab, the Decision Made by Bristol-Myers Squibb, the Reason Humphrey Was Incentivized to Advocate for Further Research of Ipilimumab, the Reason Allison Migrated to New York City, United States of America, the Problem Experienced by Allison’s Team During Migration, the Reason U.S. Pharmaceutical Corporation Pfizer Pressured Bristol-Myers Squibb and Allison’s Research, the Cancer Medication Developed by Pfizer During the Research and Development of Ipilimumab, the Standard Set by U.S. Government Agency the Food and Drug Administration for Cancer Research, Pfizer Failing to Meet This Threshold With Tremelimumab (Imjudo), the Reason Pfizer Stopped All Research of Tremelimumab, the Effect This Decision Had Upon Bristol-Myers Squibb, the Reason Allison Expected Pfizer’s Research Results of Tremelimumab, the Reason Tumor Size Increases With the Use of Tremelimumab, Allison Convincing Bristol-Myers Squibb to Continue Researching Ipilimumab, the Use and Results of Ipilimumab at the U.S. Non-Profit Cancer Research Institution and Hospital the Memorial Sloan Kettering Cancer Center, Patient Reports of Ipilimumab at the Memorial Sloan Kettering Cancer Center, the Type of Cancer Allison Was Diagnosed With, the Result of This Discovery, the Reason Bristol-Myers Squibb Launched a 5 Year Medical Research Trial for Ipilimumab, the End Date of This Medical Research Trial, the U.S. Food and Drug Administration Approving Ipilimumab, the Number of Patients Treated World Wide With Ipilimumab, and the Re-Marriage of Allison